ConductScience.org, home

Paper39230804

Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials.

Palavani LB and 15 others. J Neurooncol, 2024. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials. Papers, record 39230804. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39230804

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials.
PubMed
Journal
J Neurooncol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Meta-Analysis, Review
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.59, provisional
iCite
Revised in PubMed
2026-10-10
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Palavani LBLucca B
2Mitre LPLucas Pari
3Camerotte RRaphael
4Nogueira BVBernardo Vieira
5Canto GLGisele Lúcia
6Chen HCHsien-Chung
7Pacheco-Barrios NNiels
8Ferreira MYMárcio Yuri
9Batista SSávio
10Andreão FFFilipi Fim
11Polverini ADAllan Dias
12Montenegro TSThiago S
13Paiva WWellingson
14Ferreira CChristian
15Bertani RRaphael
16D'Amico RSRandy S

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ImmunotherapyMajor topic
GliomaMajor topic
Brain NeoplasmsMajor topic
Randomized Controlled Trials as TopicMajor topic
Humans
Immune Checkpoint Inhibitors
Cancer Vaccines
Oncolytic Virotherapy

Source PubMed

Download CSV of topics

References62

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130159779Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.Cancer Immunol Immunother2018https://conductscience.org/library/papers/30159779PubMed
226843484Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.Neuro Oncol2016https://conductscience.org/library/papers/26843484PubMed
337188783Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.Nat Med2023https://conductscience.org/library/papers/37188783PubMed
415930352Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.Clin Cancer Res2005https://conductscience.org/library/papers/15930352PubMed
537657463Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial.Lancet Oncol2023https://conductscience.org/library/papers/37657463PubMed
637004712Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.Lancet Child Adolesc Health2023https://conductscience.org/library/papers/37004712PubMed
733109586Alpha-type-1 Polarized Dendritic Cell-based Vaccination in Newly Diagnosed High-grade Glioma: A Phase II Clinical Trial.Anticancer Res2020https://conductscience.org/library/papers/33109586PubMed
815328167Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.Clin Cancer Res2004https://conductscience.org/library/papers/15328167PubMed
934850166Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial.Neuro Oncol2022https://conductscience.org/library/papers/34850166PubMed
1036517865Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.J Exp Clin Cancer Res2022https://conductscience.org/library/papers/36517865PubMed
1115256471Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.Cancer Res2004https://conductscience.org/library/papers/15256471PubMed
1232477944Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series.Front Oncol2020https://conductscience.org/library/papers/32477944PubMed
1323695293Drainage of cells and soluble antigen from the CNS to regional lymph nodes.J Neuroimmune Pharmacol2013https://conductscience.org/library/papers/23695293PubMed
1426716896Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.Oncotarget2016https://conductscience.org/library/papers/26716896PubMed
1537196069Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results.Oncologist2023https://conductscience.org/library/papers/37196069PubMed
1632750039Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme.J Clin Invest2020https://conductscience.org/library/papers/32750039PubMed
1732669604Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis.Sci Rep2020https://conductscience.org/library/papers/32669604PubMed
1836705923Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.JAMA Netw Open2023https://conductscience.org/library/papers/36705923PubMed
192033653T-lymphocyte entry into the central nervous system.J Neurosci Res1991https://conductscience.org/library/papers/2033653PubMed
2032437507Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.JAMA Oncol2020https://conductscience.org/library/papers/32437507PubMed

See all 62 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
41091250Premature mortality due to malignancies of the central nervous system in Japan: a nationwide descriptive analysis from 2000 to 2020.J Neurooncol2025https://conductscience.org/library/papers/41091250PubMed
39959084Crystallographic Structure and Antiglioma Potential of Centrolobium microchaete Seed Lectin.ACS Omega2025https://conductscience.org/library/papers/39959084PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39230804

GET https://conductscience.org/api/papers/v1/39230804/references?page=2